Overcoming Key Challenges in Bispecific and Multispecific Antibody Development
Bispecific and multispecific antibody development requires more than identifying two antigen-binding arms. Successful programs must address chain-pairing complexity, affinity balance, epitope compatibility, target specificity, functional activity, developability, and translational relevance from the earliest discovery stage.
Cyagen provides an integrated solution for bispecific and multispecific antibody projects by combining HUGO-Light™ common light-chain antibody discovery, fully human antibody mouse platforms, optimized immunization, high-throughput screening, recombinant expression, bispecific assembly support, and in vitro/in vivo validation capabilities. By generating antibody arms with a shared human κ light chain, HUGO-Light™ helps simplify downstream bispecific assembly and reduce light-chain mispairing risk, while Cyagen’s broader antibody discovery and preclinical service platforms support candidate selection from early target validation to functional lead confirmation.
How Cyagen Supports Bispecific & Multispecific Antibody Discovery
Cyagen supports bispecific and multispecific antibody programs through an integrated discovery-to-validation workflow. By combining fully human antibody mouse platforms, HUGO-Light™ common light-chain technology, optimized immunization, high-throughput antibody screening, recombinant expression, in vitro functional assays, and disease-relevant model support, Cyagen helps researchers generate high-quality antibody arms, reduce pairing-related development risks, and advance functionally validated bispecific candidates.
- Evaluate target biology, antigen format, epitope accessibility, species homology, and intended MOA.
- Project-specific planning for IgG-like bispecifics, T cell engagers, dual-targeting antibodies, receptor co-blockade, and multispecific formats.
- Choose the right discovery strategy for each target, with integrated support across mouse immunization, hybridoma, single B cell screening, recombinant expression, and hit selection.
- HUGO-Light™ combines fixed human κ common light-chain design with diverse human heavy-chain repertoires to support target-specific antibody arm discovery and bispecific reformatting.
- Identify antigen-specific hits through ELISA, FACS, hybridoma, and single B cell screening.
- Recover antibody sequences for recombinant expression, validation, and bispecific reformatting.
- Express selected antibody arms and evaluate binding, affinity, specificity, and cross-reactivity.
- Support reformatting and characterization using ELISA, FACS, BLI/SPR, internalization, and cell-based assays.
- Assess biological activity through MOA-driven in vitro functional assays.
- Connect antibody discovery with disease-relevant model support for translational validation
Solving Light-Chain Mispairing with a Common Light-Chain Discovery Strategy
Light-chain mispairing is one of the major challenges in IgG-like bispecific antibody development. In conventional workflows, independently discovered heavy and light chains may assemble into multiple unwanted molecular species during co-expression, increasing purification complexity and downstream CMC risk.
Cyagen addresses this challenge from the discovery stage by integrating HUGO-Light™ common light-chain antibody discovery with compatible heavy-chain heterodimerization strategies, such as Knobs-into-Holes. This approach enables target-specific heavy chains to pair with a shared human κ light chain, helping reduce light-chain mispairing risk and support more predictable bispecific antibody assembly.
CD3 Common Light-Chain Antibody Discovery for T-Cell Engager Development
- {{v2}}
- {{item}}
